Identification of the G994--> T missense in exon 9 of the plasma platelet-activating factor acetylhydrolase gene as an independent risk factor for coronary artery disease in Japanese men - PubMed (original) (raw)
Identification of the G994--> T missense in exon 9 of the plasma platelet-activating factor acetylhydrolase gene as an independent risk factor for coronary artery disease in Japanese men
Y Yamada et al. Metabolism. 1998 Feb.
Abstract
Platelet-activating factor (PAF) acetylhydrolase may play important roles in the pathophysiology of thrombosis and atherosclerosis related to its catalytic action in the degradation of PAF and oxidized phospholipids. A missense mutation (G--> T transversion at nucleotide 994) in the plasma PAF acetylhydrolase gene results in a Val--> Phe substitution at amino acid 279 of the mature protein and a consequent loss of catalytic activity. However, the role of a deficiency or low activity of this enzyme caused by the missense mutation in the etiology of coronary artery disease (CAD) has not been determined. The relation between this mutation and the incidence of CAD in the Japanese population is investigated herein. The genotype of plasma PAF acetylhydrolase (MM, normal; Mm, heterozygote; and mm, deficient homozygote) was determined with a polymerase chain reaction (PCR) assay for 454 patients with myocardial infarction (MI) and 602 control subjects. The frequency of the m allele was significantly higher in male patients with MI (odds ratio, 1.8) than in controls, an association that was more marked in a low-risk subgroup (odds ratio, 2.3). In contrast, the m allele was not associated with MI in women. These results indicate that the G994--> T missense mutation in exon 9 of the plasma PAF acetylhydrolase gene is an independent risk factor for CAD in Japanese men, especially low-risk individuals, but not in women.
Similar articles
- Correlations between plasma platelet-activating factor acetylhydrolase (PAF-AH) activity and PAF-AH genotype, age, and atherosclerosis in a Japanese population.
Yamada Y, Yoshida H, Ichihara S, Imaizumi T, Satoh K, Yokota M. Yamada Y, et al. Atherosclerosis. 2000 May;150(1):209-16. doi: 10.1016/s0021-9150(99)00385-8. Atherosclerosis. 2000. PMID: 10781653 - Association of a G994 -->T missense mutation in the plasma platelet-activating factor acetylhydrolase gene with risk of abdominal aortic aneurysm in Japanese.
Unno N, Nakamura T, Mitsuoka H, Uchiyama T, Yamamoto N, Saito T, Sugatani J, Miwa M, Nakamura S. Unno N, et al. Ann Surg. 2002 Feb;235(2):297-302. doi: 10.1097/00000658-200202000-00020. Ann Surg. 2002. PMID: 11807372 Free PMC article. - [Plasma platelet-activating factor acetylhydrolase (PAF-AH) deficiency as a risk factor for stroke].
Satoh K. Satoh K. Brain Nerve. 2008 Nov;60(11):1319-24. Brain Nerve. 2008. PMID: 19069165 Review. Japanese. - Platelet-activating factor acetylhydrolase: is it good or bad for you?
Chen CH. Chen CH. Curr Opin Lipidol. 2004 Jun;15(3):337-41. doi: 10.1097/00041433-200406000-00015. Curr Opin Lipidol. 2004. PMID: 15166791 Review.
Cited by
- Association Lp-PLA2 Gene Polymorphisms with Coronary Heart Disease.
Ma S, Ding L, Cai M, Chen L, Yan B, Yang J. Ma S, et al. Dis Markers. 2022 Jul 2;2022:9775699. doi: 10.1155/2022/9775699. eCollection 2022. Dis Markers. 2022. PMID: 35818585 Free PMC article. - Structural Modeling of Wild and Mutant Forms of Human Plasma Platelet Activating Factor-Acetyl Hydrolase Enzyme.
Khan MI, Hariprasad G. Khan MI, et al. J Inflamm Res. 2020 Dec 16;13:1125-1139. doi: 10.2147/JIR.S274940. eCollection 2020. J Inflamm Res. 2020. PMID: 33364808 Free PMC article. - Human Secretary Phospholipase A2 Mutations and Their Clinical Implications.
Khan MI, Hariprasad G. Khan MI, et al. J Inflamm Res. 2020 Sep 16;13:551-561. doi: 10.2147/JIR.S269557. eCollection 2020. J Inflamm Res. 2020. PMID: 32982370 Free PMC article. Review. - Val279Phe variant of Lp-PLA2 is a risk factor for a subpopulation of Indonesia patients with acute myocardial infarction.
Cahyaningtias M, Rohman MS, Widodo, Wahjono Adi A, Yuda R, Indrayana Y, Putri JF, Rusdianto, Lukitasari M, Hendrawan D. Cahyaningtias M, et al. Genes Dis. 2016 Sep 17;3(4):289-293. doi: 10.1016/j.gendis.2016.08.002. eCollection 2016 Dec. Genes Dis. 2016. PMID: 30258899 Free PMC article. - Pharmacogenetic meta-analysis of baseline risk factors, pharmacodynamic, efficacy and tolerability endpoints from two large global cardiovascular outcomes trials for darapladib.
Yeo A, Li L, Warren L, Aponte J, Fraser D, King K, Johansson K, Barnes A, MacPhee C, Davies R, Chissoe S, Tarka E, O'Donoghue ML, White HD, Wallentin L, Waterworth D. Yeo A, et al. PLoS One. 2017 Jul 28;12(7):e0182115. doi: 10.1371/journal.pone.0182115. eCollection 2017. PLoS One. 2017. PMID: 28753643 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases
Miscellaneous